Moleculin Biotech Inc (MBRX): Next-Year EPS Estimate 64.18%
As of 2026-11-12, Moleculin Biotech Inc (MBRX) has a next-year EPS growth estimate of 64.18%. Featured in our EPS revision report on 2026-08-12.
Analyst estimates for MBRX have remained steady in the most recent observable window, with next-year EPS growth projected at 64.18%. Current-year growth stands at 88.51%.
What's Driving This
The primary structural driver is the 2026-08-28 analyst revision raising next-year EPS growth from 42.10% to 64.18%. The most plausible catalyst among recent headlines is Moleculin’s positive Phase 2/3 MIRACLE
Generated 2026-10-26 from news as of 2026-10-26
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 64.18%
- EPS growth this year
- 88.51%
- EPS next quarter (est)
- -$8.87
- Last price
- $8.06
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-12 | 64.18% | 88.51% | -$8.87 | $8.06 |
| 2026-11-11 | 64.18% | 88.51% | -$8.87 | $8.10 |
| 2026-11-10 | 64.18% | 88.51% | -$8.87 | $8.06 |
| 2026-11-09 | 64.18% | 88.51% | -$8.87 | $8.66 |
| 2026-11-07 | 64.18% | 88.51% | -$8.87 | $8.70 |
| 2026-11-06 | 64.18% | 88.51% | -$8.87 | $8.70 |
| 2026-11-05 | 64.18% | 88.51% | -$8.87 | $8.73 |
| 2026-11-04 | 64.18% | 88.51% | -$8.87 | $8.46 |
| 2026-11-03 | 64.18% | 88.51% | -$8.87 | $8.30 |
| 2026-11-02 | 64.18% | 88.51% | -$8.87 | $8.32 |
| 2026-10-31 | 64.18% | 88.51% | -$8.87 | $7.90 |
| 2026-10-30 | 64.18% | 88.51% | -$8.87 | $7.90 |
| 2026-10-29 | 64.18% | 88.51% | -$8.87 | $8.72 |
| 2026-10-28 | 64.18% | 88.51% | -$8.87 | $8.74 |
| 2026-10-27 | 64.18% | 88.51% | -$8.87 | $9.27 |
| 2026-10-26 | 64.18% | 88.51% | -$8.87 | $7.09 |
| 2026-10-23 | 64.18% | 88.51% | -$8.87 | $6.50 |
| 2026-10-22 | 64.18% | 88.51% | -$8.87 | $5.89 |
| 2026-10-21 | 64.18% | 88.51% | -$8.87 | $6.31 |
| 2026-10-20 | 64.18% | 88.51% | -$8.87 | $6.19 |
| 2026-10-19 | 64.18% | 88.51% | -$0.44 | $0.26 |
| 2026-10-16 | 64.18% | 88.51% | -$0.44 | $0.28 |
| 2026-10-15 | 64.18% | 88.51% | -$0.44 | $0.37 |
| 2026-10-14 | 64.18% | 88.51% | -$0.44 | $0.41 |
| 2026-10-13 | 64.18% | 88.51% | -$0.44 | $0.44 |
| 2026-10-12 | 64.18% | 88.51% | -$0.44 | $0.41 |
| 2026-10-11 | 64.18% | 88.51% | -$0.44 | $0.44 |
| 2026-10-10 | 64.18% | 88.51% | -$0.44 | $0.44 |
| 2026-10-09 | 64.18% | 88.51% | -$0.44 | $0.44 |
| 2026-10-08 | 64.18% | 88.51% | -$0.44 | $0.42 |
Reports Featuring MBRX
Recent News
- Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE TrialGlobeNewswire
- MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of SignificanceStocktwits
- Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than ControlGlobeNewswire
Screen Performance
Aggregate stats across all 2145 tickers our top-EPS-revision screen has flagged over the past 225 days.
- Median return since detection
- -2.9%
- % of tickers in the green
- 43%
- Median return on winners
- +22.8%
- Large revisions captured
- 2246
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Moleculin Biotech Inc's next-year EPS growth estimate?▾
As of 2026-11-12, Moleculin Biotech Inc (MBRX) has a next-year EPS growth estimate of 64.18%, based on analyst consensus.
What sector and industry does Moleculin Biotech Inc belong to?▾
Moleculin Biotech Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. MBRX appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Moleculin Biotech Inc (MBRX) appears here because it was detected by our daily top-EPS-revision-performer screen.